Literature DB >> 15577313

Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.

Michela Mantelli1, Lorenza Pastorino, Paola Ghiorzo, Monica Barile, William Bruno, Sara Gargiulo, Maria Pia Sormani, Sara Gliori, Stefania Vecchio, Paola Ciotti, Mario Roberto Sertoli, Paola Queirolo, Alisa M Goldstein, Giovanna Bianchi-Scarrà.   

Abstract

Although the presence of multiple cases of melanoma on the same side of a family is the best predictor of germline CDKN2A mutation, other features (i.e. early age at onset) may be useful to identify carriers. We analysed the records of 682 hospital-based Ligurian melanoma patients. Of these, 238 cases (34 familial, 14 non-familial multiple primary and 190 non-familial single primary melanomas) were consecutively enrolled for screening of the CDKN2A and CDK4 genes. Screening of the 34 familial patients revealed that nine were carriers of the CDKN2A G101W founder mutation. Of the 14 non-familial multiple primary melanoma patients, three carried the G101W founder mutation and one the P48T mutation. For the non-familial patients with a single melanoma, 17 of 190 carried germline CDKN2A mutations, with most (16/17) carrying the G101W Ligurian founder mutation and one a novel single base pair substitution, D74Y. The effect of mutation on age at diagnosis was significant (P=0.012) after correcting for melanoma type (familial or non-familial), number of primaries (single or multiple), gender and disease occurrence (incident or prevalent). Early age at onset may be a good predictor of CDKN2A mutation in Liguria, where the G101W founder mutation is prevalent among melanoma patients, independent of family history.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577313     DOI: 10.1097/00008390-200412000-00002

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  8 in total

Review 1.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Authors:  Sara Di Lorenzo; Daniele Fanale; Bartolo Corradino; Valentina Caló; Gaetana Rinaldi; Viviana Bazan; Antonio Giordano; Adriana Cordova; Antonio Russo
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

Review 3.  Epidemiological and genetic factors underlying melanoma development in Italy.

Authors:  Giuseppe Palmieri; Maria Colombino; Milena Casula; Mario Budroni; Antonella Manca; Maria Cristina Sini; Amelia Lissia; Ignazio Stanganelli; Paolo A Ascierto; Antonio Cossu
Journal:  Melanoma Manag       Date:  2015-05-18

Review 4.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

5.  Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

Authors:  William Bruno; Claudia Martinuzzi; Bruna Dalmasso; Virginia Andreotti; Lorenza Pastorino; Francesco Cabiddu; Marina Gualco; Francesco Spagnolo; Alberto Ballestrero; Paola Queirolo; Federica Grillo; Luca Mastracci; Paola Ghiorzo
Journal:  Oncotarget       Date:  2017-12-14

6.  Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.

Authors:  W Bruno; B Dalmasso; M Barile; V Andreotti; L Elefanti; M Colombino; I Vanni; E Allavena; F Barbero; E Passoni; B Merelli; S Pellegrini; F Morgese; R Danesi; V Calò; V Bazan; A V D'Elia; C Molica; F Gensini; E Sala; V Uliana; P F Soma; M Genuardi; A Ballestrero; F Spagnolo; E Tanda; P Queirolo; M Mandalà; I Stanganelli; G Palmieri; C Menin; L Pastorino; P Ghiorzo
Journal:  ESMO Open       Date:  2022-06-28

7.  Management of melanoma families.

Authors:  Wilma Bergman; Nelleke A Gruis
Journal:  Cancers (Basel)       Date:  2010-04-16       Impact factor: 6.639

8.  CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study.

Authors:  Jose D Tovar-Parra; Luz D Gutiérrez-Castañeda; Sebastián R Gil-Quiñones; Jhon A Nova; Leonardo Pulido
Journal:  Biomed Res Int       Date:  2020-10-10       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.